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Abstract
Introduction Histopathological features of BRCA1 and BRCA2
tumours have previously been characterised and compared with
unselected breast tumours; however, familial non-BRCA1/2
tumours are less well known. The aim of this study was to
characterise familial non-BRCA1/2  tumours and to evaluate
routine immunohistochemical and pathological markers that
could help us to further distinguish families carrying BRCA1/2
mutations from other breast cancer families.
Methods Breast cancer tissue specimens (n = 262) from 25
BRCA1, 20 BRCA2  and 74 non-BRCA1/2  families were
studied on a tumour tissue microarray. Immunohistochemical
staining of oestrogen receptor (ER), progesterone receptor
(PgR) and p53 as well as the histology and grade of these three
groups were compared with each other and with the respective
information on 862 unselected control patients from the
archives of the Pathology Department of Helsinki University
Central Hospital. Immunohistochemical staining of erbB2 was
also performed among familial cases.
Results BRCA1-associated cancers were diagnosed younger
and were more ER-negative and PgR-negative, p53-positive and
of higher grade than the other tumours. However, in multivariate
analysis the independent factors compared with non-BRCA1/2
tumours were age, grade and PgR negativity. BRCA2 cases did
not have such distinctive features compared with non-BRCA1/
2 tumours or with unselected control tumours. Familial cases
without BRCA1/2 mutations had tumours of lower grade than
the other groups.
Conclusions BRCA1 families differed from mutation-negative
families by age, grade and PgR status, whereas ER status was
not an independent marker.
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Introduction
Women predisposed to hereditary or familial breast cancer
form a heterogeneous group. It would be useful if we could
identify carriers of the high-risk BRCA1 and BRCA2 genes
and target the expensive and time-consuming genetic test-
ing to individuals who most probably carry those mutations.
Besides family history, histopathological markers could
also be useful in distinguishing patients and families likely
to carry a BRCA1/2 germline mutation from mutation-neg-
ative families and breast cancer patients in general.
Several studies have compared the characteristics of
breast cancers in BRCA1 carriers and in sporadic controls.
Distinct features between BRCA1-associated tumours
have been found, such as high tumour grade, oestrogen
receptor (ER) negativity, and overexpression of p53 [1-3].
In addition, negativity for progesterone receptor (PgR)
[3,4], a higher proportion of medullary and atypical medul-
lary carcinomas [5,6], and tumours with a low expression of
c-erbB-2 [1,4,6] have been detected. Besides the higher
proportion of medullary histology, a higher frequency of
ductal carcinoma has also been reported [7,8]. Recently,
cDNA expression analyses have suggested a basal
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epithelial phenotype for BRCA1 tumours [9] and expres-
sion of cytokeratins 5/6 has been associated with BRCA1
tumours [10].
Among BRCA2-associated tumours, a slight increase has
been observed in the incidence of lobular or tubulolobular
carcinomas [11,12]. However, results are inconsistent, and
in most cases no significant difference has been found
between BRCA2-associated tumours and sporadic can-
cers [1,4,6,13]. Complementary DNA (cDNA) expression
analysis has suggested distinct expression profiles for
BRCA2 tumours as well [14].
It has been clear for some time that in many families hered-
itary susceptibility is not due to the BRCA1 or BRCA2
genes [15,16]. Only a few studies have evaluated the fea-
tures of this large group of families. It would be crucial for
genetic counselling and for our understanding of tumour
development to learn more about these patients. Lakhani
and colleagues [17] studied the pathology of 82 familial
breast cancers not attributable to BRCA1 or BRCA2 muta-
tions, and they found these non-BRCA1/2 cancers to be of
lower grade, to show less pleomorphism and to have a
lower mitotic count than sporadic cancers or BRCA muta-
tion-positive cancers. No other features differed signifi-
cantly in their study. However, they did not examine
immunohistochemical characteristics. There has been only
one study so far that has characterised the immunohisto-
chemical features of familial non-BRCA1/2 cancers: Pala-
cios and colleagues [18] studied immunohistochemical
staining and histopathology and compared 37 non-
BRCA1/2  cancers with 20 BRCA1-associated and 18
BRCA2-associated cancers, and also with unselected
control cancers. They similarly found those to be of lower
grade than in all the other three groups. In comparison with
sporadic cancers they were also more frequently p53-neg-
ative and erbB2-negative, and expressed reduced E-cad-
herin and β-catenin. However, the number of patients in this
study was small and it was restricted to only a univariate
analysis of the studied parameters.
Most of the previous studies on BRCA1-associated and
BRCA2-associated cancers have studied highly selected
patient groups, but in the present study families were col-
lected with a simple criterion of at least three first-degree or
second-degree relatives with breast or ovarian cancer with
no restriction on age. We studied an extensive material of
152 non-BRCA1/2 tumours, and also 110 tumours from
BRCA1/2 families for histopathological features as well as
for the immunohistochemical expression of ER, PgR, p53
and erbB2. We describe here the histopathological profile
of the tumours originating from non-BRCA1/2 breast can-
cer families and also present a multivariate analysis to find
the independent markers that can further help in distin-
guishing especially BRCA1 mutation-positive families from
other familial cases.
Patients and methods
Familial breast cancer patients were identified and col-
lected by a systematic screening for family history at the
Department of Oncology, Helsinki University Central Hos-
pital, as described previously [19]. We defined breast can-
cer families by the selection criterion of at least three first-
degree or second-degree relatives with breast or ovarian
cancer (including the proband). We confirmed the geneal-
ogy of the families through population registries, and can-
cer diagnoses through the Finnish Cancer Registry. In this
study we included 25 BRCA1 families, 20 BRCA2 families
and 74 families not associated with either of these genes
(non-BRCA1/2 families) (Table 1). All families had previ-
ously been tested for BRCA1 and BRCA2 mutations by
mutation analysis of the whole coding sequences and
exon/intron boundaries of the genes as described [16,20]
or tested for all previously reported 18 Finnish BRCA1 and
BRCA2 mutations [16,20-22].
We collected all the paraffin blocks of all the primary breast
cancers that were available (n = 262) from these families.
However, cases tested to be non-carriers in the mutation-
positive families were excluded. In total, 51 cancers from
the 25 BRCA1 families, 59 cancers from the 20 BRCA2
families and 152 cancers from the 74 non-BRCA1/2 fami-
lies were included in this study. We studied the haematox-
ylin and eosin sections of the original blocks to achieve
histological diagnosis and grading. Grading was performed
according to Scarff-Bloom-Richardson modified by Elston
and Ellis [23]. The most representative area of the tumour
was punched to produce a hereditary breast cancer tissue
microarray including two cores (diameter 0.6 mm) from all
of the original blocks. The array block of non-BRCA1/2
cases was described previously by Vahteristo and col-
leagues [24]. All of the microarray slides were stained with
routine methods by antibodies against ER, PgR, p53 and
erbB2 in the same pathology laboratory as our controls. In
brief, 5 µm sections were cut from paraffin-embedded
blocks, deparaffinated in xylene, and dehydrated in a series
of graded alcohols. The sections were pretreated in a
microwave oven and incubated overnight with antibody.
Antibodies for ER (dilution 1:50) and c-erbB-2 (NCL-
CB11; dilution 1:400) were purchased from Novocastra
(Newcastle upon Tyne, UK), and those for PgR (dilution
1:250) and p53 (dilution 1:100) were from Dako (Copen-
hagen, Denmark). The evaluation of the staining results was
similar to that used in routine diagnostics and samples
were considered positive when 10%, 10% and 20% of the
cells were stained for ER, PgR and p53, respectively. Sam-
ples having a moderate or intense staining of the entire
membrane in more than 10% of the tumour cells (2+ andAvailable online http://breast-cancer-research.com/content/7/1/R93
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3+) were considered to be c-erbB-2-positive. Other stain-
ing patterns were considered to be negative (0 and 1+).
As a control group we drew from the archives of the Pathol-
ogy Department at Helsinki University 862 unselected
breast cancer tumours from the years 1997–2001 that
were scored by the same pathologist (PH) as the tumours
of the hereditary breast cancer patients.
Statistical analysis was conducted with SPSS version 8.0
for Windows. We tested the differences in continuous var-
iables by the Mann–Whitney test and in dichotomous
variables by the χ2 test or Fisher's exact test. In multivariate
analysis, we used logistic regression analysis (stepwise
backwards logistic regression, 99%). All P values are two-
sided.
Permissions for this study were obtained from the ethics
committees of the Department of Oncology and the
Department of Obstetrics and Gynaecology, Helsinki Uni-
versity Central Hospital, and of the Ministry of Social Affairs
and Health in Finland. Blood and tumour samples were
used in this study with written informed consent from
probands and family members.
Results
BRCA1-associated cancers were diagnosed at a younger
age than unselected breast cancers (median ages 44 and
56 years, respectively; P ≤ 0.0005) and they were more
often ER-negative and PgR-negative, p53-positive and of
higher grade (Table 2). The frequency of medullary histol-
ogy was also higher. In logistic regression analysis, taking
into account all of these factors, the independent factors
were age (P ≤ 0.0005), ER status (P = 0.0597), PgR status
(P = 0.0170) and medullary histology (P = 0.0636).
In comparison with familial non-BRCA1/2 cancers (median
age 55 years), a univariate analysis of BRCA1 tumours
showed similar differences from unselected cancers (Table
2). However, in multivariate analysis, taking into account the
same factors, the independent factors were age (P  =
0.0012), grade (P  = 0.0014) and PgR negativity (P  =
0.0196) (Table 3). We did not find any significant differ-
ences between groups of tumours from carriers with
different mutations or when comparing tumours from the
carriers of the mutations at the 5' end or the 3' end of the
gene.
BRCA2-associated cancers were diagnosed at younger
age (median age 47 years) than unselected breast cancers
(median age 56 years, P ≤ 0.0005). They were also more
often ER-negative and PgR-negative (Table 2). In multivari-
ate analysis, the independent factors were age (P  ≤
0.0005), PgR status (P = 0.0365) and p53 status (P =
0.0318).
When compared with familial non-BRCA1/2 cancers, the
BRCA2-associated cancers were diagnosed at a younger
age (median age 47 years; among non-BRCA1/2 patients
the median age was 55 years; P ≤ 0.0005). No other vari-
able differed significantly from non-BRCA1/2  cancers
(Table 2). We did not find any significant differences
between tumours originating from different mutation carri-
ers or when comparing tumours from the carriers of muta-
tions from the OCCR (Ovarian Cancer Cluster region) (n =
7) and the end of the gene. In a logistic regression analysis
comparing BRCA2-associated cancers with non-BRCA1/
2 cancers and taking into account age, grade and all tested
histological and immunohistochemical factors, the only
independently significant factor was age (P  = 0.0001)
(Table 2).
Among familial non-BRCA1/2 patients, the median age of
onset was marginally younger (55.0 years) than among the
unselected controls (56.0 years, P = 0.060). The frequency
of grade I and II tumours was much higher among the non-
BRCA1/2  group than in the unselected control group
(odds ratio 1.8, P = 0.009) (Table 2) or in the BRCA1 and
BRCA2 groups. In a multiple regression analysis compar-
ing non-BRCA1/2 tumours with unselected controls, grade
(odds ratio 0.54, P ≤ 0.00005) and ER status (odds ratio
2.4 for negative ER status, P = 0.0006) were the independ-
ent significant factors.
The erbB2 results were very similar in the three groups of
familial cases, with 18.6%, 15.1% and 17.4% of the
BRCA1,  BRCA2  and non-BRCA1/2  tumours, respec-
tively, expressing the erbB2 antigen (Table 2).
Discussion
Although genetic testing for BRCA1 and BRCA2 muta-
tions is available, it is expensive, time-consuming and
stressful to patients. Several models have therefore been
developed for evaluating the probability of carrying a
BRCA1 or BRCA2 mutation [25-30]. In our previous study
of Finnish breast cancer families [15,29], multivariate anal-
ysis suggested simple family history criteria for breast
cancer onset under the age of 40 years and the presence
of ovarian cancer to be most strongly associated with
BRCA1/2 mutation status [29]. However, in addition to
family history, it is important to find other markers that could
help to identify mutation carriers. In many countries, mark-
ers that are already routinely used, such as ER, PgR, p53
and the grade of the tumour, could serve as an excellent
tool to aid distinguishing families because this information
is easily available. In this study, we found that BRCA1-
associated cancers have a different histological profile and
can be distinguished from other familial cancers. Specifi-
cally, multivariate analysis revealed age, grade and PgR
negativity as the independent factors distinguishing
BRCA1  tumours from familial non-BRCA1/2  tumours.Breast Cancer Research    Vol 7 No 1    Eerola et al.
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BRCA2-associated cancers did not differ greatly, but
those were also significantly younger and there was a trend
towards higher grade than among familial non-BRCA1/2
cancers.
ER negativity has previously been highlighted to be linked
to BRCA1 tumours. It was obvious in this study too. Our
results are consistent with, for example, the study of
Lakhani and colleagues [4], in which BRCA1 cancers were
clearly more ER-negative (90%) than unselected control
cancers (35%). However, in our study the overall percent-
ages of ER-negative cancers were much lower for both
groups (67% among BRCA1 and 19% among unselected
controls). This might be due to a different age distribution
Table 1
Mutation spectrum and numbers of families and patients by mutation
Gene Mutation Number of families Number of patients
BRCA1 ex 10 782 del AA 1 1
ex 11 1047 C→T11
ex 11 1731 C→T12
ex 11 1806 C→T11
ex 11 1924 del A 1 1
ex 11 2592 ins A 1 2
ex 11 2803 del AA 1 3
ex 11 3604 del A 3 3
ex 11 3744 del T 2 2
ex 11 3904 C→A11
ex 11 4153 del A 1 1
int 11 4216 (- 2) A→G4 9
ex 13 4446 C→T2 1 4
ex 14 4599 G>T 1 3
ex 17 5145 del 11 1 4
ex 20 5370 C→T11
ex 20 5382 ins C 2 2
Any 25 51
BRCA2 ex 9 999 del TCAAA 5 22
ex 10 1822 G→T11
ex 11 4075 del GT 1 1
ex 11 4081 ins A 1 2
ex 11 5797 G→T11
ex 11 6496 del CA 1 2
ex 11 6503 del TT 1 1
ex 15 7708 C→T3 1 2
ex 18 8555 T→G16
int 23 9346 (- 2) A→G5 1 1
Any 20 59
Non-BRCA1/2 74 152Available online http://breast-cancer-research.com/content/7/1/R93
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because the prevalence of ER-negative cases is higher
among young breast cancer patients [31,32] and our famil-
ial cases were not selected on the basis of young age of
diagnosis. Furthermore, there is a very high coverage mam-
mography screening (in the general age group 50–60
years) in Finland, aiding in finding asymptomatic cancers,
which are more often ER-positive as well as being of lower
grade and PgR-positive [33].
In this study, we specifically sought to compare BRCA1
cancers with familial non-BRCA1/2 cancers as well, which
is the relevant question in a clinical and genetic counselling
setting. Surprisingly, in this analysis the ER status was not
an independent marker in multiple regression. More impor-
tant markers were age, PgR status and grade. ER status
was dependent on age and grade. Palacios and colleagues
[18] also compared BRCA1  cases with non-BRCA1/2
cases (cases from families with at least three affected with
breast cancer, one of them diagnosed under 50 years of
age). In a univariate analysis, the results showing ER and
PgR negativity, p53 overexpression and high grade were
very similar to ours. However, multivariate analysis was not
used for evaluating independent markers. Recently, cDNA
expression analyses have suggested a basal epithelial phe-
notype for BRCA1  tumours [9]. Epithelial phenotype is
associated with breast cancers that express neither ER nor
erbB2, a feature that also occurs in BRCA1-mutation carri-
ers [10]. A large majority (20 of 22 tumours) of BRCA1-
associated tumours were also ER-negative and erbB2-neg-
ative in our study, in accordance with the high frequency of
ER-negative tumours among BRCA1  carriers. The fre-
quency of erbB2 expression was similar in all three groups
of familial tumours.
BRCA2-associated tumours did not differ significantly from
familial non-BRCA1/2 tumours, although they were diag-
nosed at an earlier age. Our results on BRCA2 cancers
were quite similar to those of Palacios and colleagues [18]
Table 2
Analysis of features among BRCA1-, BRCA2- and non-BRCA1/2-associated cancers and in unselected cancers
N (frequency, %) P
Feature BRCA1 BRCA2 Non-BRCA1/2 Unselected
Histology
Ca ductale 37 (72.5) 37 (62.7) 102 (67.1) 561 (65.1)
Ca lobulare 8 (15.7) 17 (28.8) 30 (19.7) 219 (25.4)
Ca medullare 5 (9.8) - 3 (2.0) 20 (2.3) 0.013*, 0.001**
Others 1 (2.0) 5 (8.5) 17 (11.2) 62 (7.2)
Grade
I 3 (6.1) 12 (23.1) 46 (32.4) 152 (23.3)
II 11 (22.4) 26 (50.1) 66 (46.5) 289 (44.4)
III 35 (71.4) 14 (26.9) 30 (21.1) 210 (32.3)
I–II 14 (28.6) 38 (73.1) 112 (78.9) 441 (67.7) ≤ 0.0005*, <0.0005**, 0.009****
Immunohistochemistry
ER- 28 (66.7) 17 (32.1) 40 (27.0) 167 (19.4) ≤ 0.0005*, <0.0005**, 0.026***, 0.035****
ER+ 14 (33.3) 36 (67.9) 108 (73.0) 692 (80.6)
PgR- 37 (84.1) 28 (51.9) 67 (45.3) 312 (36.2) ≤ 0.0005*, <0.0005**, 0.021***, 0.036****
PgR+ 7 (15.9) 26 (48.1) 81 (54.7) 549 (63.8)
p53- 27 (62.8) 42 (82.4) 118 (78.7) 628 (74.0) 0.034*, <0.0005**
p53+ 16 (37.2) 9 (17.6) 32 (21.3) 221 (26.0)
erbB2- 35 (81,4) 45 (84,9) 109 (82,6) NA
erbB2+ 8 (18,6) 8 (15,1) 23 (17,4) NA
*BRCA1 versus non-BRCA1/2 tumours; **BRCA1 versus unselected breast tumours; ***BRCA2 versus unselected breast tumours; ****non-
BRCA1/2 tumours versus unselected breast tumours.
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and Lakhani and colleagues [17], although in the former
study the BRCA2  cancers were more ER-positive and
PgR-positive (on the basis of smaller sample set of 14
cases).
BRCA1  and  BRCA2  mutations have been detected in
quite a low proportion of breast cancer families. In Finland,
among families with three affected first-degree or second-
degree relatives without age restrictions, the proportions
were 10% and 11% for BRCA1 and BRCA2, respectively
[16,20]. Thus an important and large group of families is
not due to mutations in the BRCA1 and BRCA2 genes. In
this study, the familial non-BRCA1/2 cancers were diag-
nosed at a marginally younger age than those among unse-
lected cases, and were more often of lower grade than the
control cancers or BRCA1 and BRCA2 cancers. These
factors might be influenced by recall bias because patients
having affected relatives undergo diagnostic procedures
earlier than women with no family history of breast cancer.
However, no such influence is seen for BRCA1 or BRCA2
cases, which often have a much stronger family back-
ground of cancer. Furthermore, a lower grade among famil-
ial non-BRCA1/2 cases has been detected elsewhere as
well [17,18].
In comparison with BRCA1 or BRCA2 cancers, familial
non-BRCA1/2  cancers represented a much greater
number of ER-positive and PgR-positive cases; however, in
comparison with the unselected control group they were
more receptor-negative. The frequency of ER-positive can-
cers among our control cancers is quite high, which might
be due to a later year of diagnosis than for non-BRCA1/2
cancers and in general because of age distribution [34],
mammography screening [33] or ethnic differences [35] in
different populations.
Conclusions
In this report we have characterised familial non-BRCA1/2
tumours and evaluated routine immunohistochemical and
pathological markers that could help us to further distin-
guish families carrying BRCA1/2  mutations from other
breast cancer families. It is noteworthy here that, although
ER negativity has been considered a hallmark of BRCA1
tumours, logistic regression analysis indicated that this was
not an independent marker but was dependent on the age
of diagnosis and tumour grade. When considering the pos-
sibility of mutation testing in the context of genetic counsel-
ling, for instance, it would be important to consider the
tumour characteristics specifically in comparison with
those from other breast cancer families. It also seems cru-
cial to consider the histopathological features with regard
to the age of the patients. In this study, the independent
markers that distinguished BRCA1 carrier tumours from
familial non-BRCA1/2 tumours were earlier age of diagno-
Table 3
Logistic regression analysis of features of breast cancers among BRCA1- and BRCA2-associated cases in comparison with non-
BRCA1/2 cases
Odds ratio (95% confidence interval, P)
Feature BRCA1 BRCA2
First step:
Age (continuous) 0.94 (0.91–0.98, 0.0009) 0.94 (0.91–0.97, 0.0001)
Grade (continuous) 3.78 (1.70–8.39, 0.0011) 1.27 (0.71–2.26, 0.42)
ER+ 1.0 (referent) 1.0 (referent)
ER- 0.91 (0.28–2.90, 0.88) 0.85 (0.32–2.29, 0.75)
PgR+ 1.0 (referent) 1.0 (referent)
PgR- 4.18 (1.26–13.87, 0.019) 1.82 (0.75–4.38, 0.18)
p53+ 1.0 (referent) 1.0 (referent)
p53- 1.96 (0.74–5.18, 0.18) 1.61 (0.63–4.12, 0.34)
Final step after stepwise regression:
Age (continuous) 0.94 (0.92–0.98, 0.0012) 0.94 (0.92–0.97, 0.0001)
Grade (continuous) 3.25 (1.58–6.69, 0.0014)
PgR+ 1.0 (referent)
PgR- 3.45 (1.22–9.80, 0.02)
ER, oestrogen receptor; PgR, progesterone receptor.Available online http://breast-cancer-research.com/content/7/1/R93
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sis, negative PgR status and higher grade. These immuno-
histochemical and pathological characteristics of the
tumours, which are available in routine pathological diag-
nostics, should be of value in evaluating the possibility of
mutation and in targeting mutation screening in such fami-
lies, especially when considering the characteristics of sev-
eral tumours in the family and combined with the family
history of cancer.
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